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Purpose: Many patients with asthma still have insufficient disease control, despite the 
availability of effective treatment options. A substantial proportion of patients appear to 
rely more on short-acting beta2-agonist (SABA) rather than on anti-inflammatory mainte-
nance treatment. The aim of this study was to describe differences in indicators of asthma 
symptoms and exacerbations among patients using more or less SABA than the guideline- 
recommended threshold of <3 times/week.
Patients and Methods: Data from Dutch respondents in the European REcognise Asthma 
and LInk to Symptoms and Experience (REALISE) survey were used in this post hoc 
analysis. The survey included asthma patients aged 18–50 years with at least two prescrip-
tions for their asthma in the past two years. SABA use was categorized into two groups: <3 
(low-SABA users) or ≥3 (high-SABA users) times in the last week.
Results: Of the 736 asthma patients, 21% did not use SABA and 19% used SABA 1 to 2 
times (all low SABA users) and 60% used SABA ≥3 times (high SABA users) in the last 
week. The majority of high and low SABA users also reported using an ICS-containing 
treatment. Significant differences were found for all indicators related to exacerbations 
(p<0.001): high SABA users more frequently used antibiotics and oral steroids, more 
frequently visited the emergency departments or needed an overnight hospital stay. 
Indicators of asthma symptoms were not significantly different between both groups.
Conclusion: The majority of a Dutch asthmatic population reported high SABA use and 
had frequent moderate/severe exacerbations. More effective interventions are needed to 
change healthcare providers’ and patients’ behaviours to improve care and reduce SABA 
(over)use.
Keywords: asthma, short acting beta2-agonist, SABA, primary health care, adverse effects, 
guidelines
Introduction
According to the Global Initiative for Asthma (GINA) report in 2019, the primary 
goals of asthma management are to achieve and enhance control of disease, 
minimize future risk of exacerbations/deaths and reduce fixed airflow limitation, 
while at the same time minimizing side effects of treatment. In clinical practice, 
meeting these goals and thus managing uncontrolled asthma involves a continuous 
cycle of regular patient assessment, review of medications, treatment adjustment, 
and evaluation of the patient’s response to facilitate treatment decisions.1
Despite the guidelines and the availability of multiple effective treatment 
options, asthma control is still inadequate in many patients. In Europe, a large 
proportion of asthma patients has uncontrolled asthma.2 A web-survey in over 2500 
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Australian adults with asthma revealed poor self-rated 
symptom control in approximately half of the participants, 
with one-third of patients reporting an urgent healthcare 
need in the previous year.3 Poor asthma control is strongly 
associated with a higher risk of exacerbations, poor quality 
of life, reduced productivity and increased healthcare 
utilization.4,5
A marker for poor asthma control is high use of short- 
acting beta2-agonists (SABA).6 Many patients appear to 
rely primarily on their SABA rather than their anti- 
inflammatory controller therapy (inhaled corticosteroids 
(ICS)), thereby failing to treat the underlying inflammation 
resulting in uncontrolled asthma.6,7 Moreover, high use of 
SABA therapy comes with a range of adverse conse-
quences, including increased asthma-related mortality and 
asthma-related healthcare utilization.8–10 In addition, the 
dispensation of more than twelve SABA inhalers to one 
individual per year is associated with an increased risk of 
asthma-related mortality.11
One of the aspects that may encourage high SABA use 
is the fundamental asthma management principle of using 
SABA exclusively on an “as needed” basis.12 This has 
been the main recommendation for many years, causing 
SABA use to become habitual under asthma patients. 
GINA has recognised this unfortunate by-effect and has 
therefore decided to make a drastic change in their updated 
report regarding the recommendations on SABA use in 
asthma management. In GINA’s 2019 report, it is high-
lighted that for the safety of the patients, SABA-only 
treatment is no longer recommended for asthma treatment 
in adults and adolescents not even in the milder stages of 
asthma. As a replacement, the combination of an as 
needed ICS with a fast-acting long-acting beta2-agonist 
(LABA) is now recommended as the initial starting treat-
ment for patients with mild asthma. This strategy is ben-
eficial to the exacerbation rate as well as to symptoms.1
The Dutch general practitioners’ (GPs’) asthma guide-
lines define high SABA use as the use of 3 or more 
SABAs per week. In the case of high SABA use, patients 
should consult the GP for evaluation of the medication 
strategy. The use of 3 or more SABAs per week is 
regarded as a cut-off for adding ICS and 2 times or less 
needs no additional therapeutic adjustments. This places 
the Dutch GP guidelines in accordance with the GINA 
2018 recommendation.13–15 For healthcare providers to 
achieve an optimal informed clinical decision making 
and an easy assessment of SABA, more insight is needed 
into the (high) SABA use in the previous week as reported 
by the patient. The current study reviews SABA usage in 
the Netherlands and studies whether there are differences 
in indicators of asthma symptoms and exacerbations 
between patients using either more or less SABA than 
the threshold of 3 times/week.
Patients and Methods
Study Design and Population
This descriptive study is based on a post hoc analysis on 
data of Dutch respondents to the European REcognise 
Asthma and LInk to Symptoms and Experience 
(REALISE) survey.2,16
The REALISE survey was conducted online in eleven 
European countries (Austria, Belgium, Finland, France, 
Germany, Italy, the Netherlands, Norway, Spain, Sweden, 
and the United Kingdom) in 2012, by Incite Marketing 
Planning Limited (London, United Kingdom), in accor-
dance with the Codes of Conduct of the Market Research 
Society, European Pharmaceutical Marketing Research 
Association and Association of the British 
Pharmaceutical Industry, and guidelines from the British 
Healthcare Business Intelligence Association. Data were 
managed in accordance with the Data Protection Act (UK, 
1998). It was a qualitative, online questionnaire-based 
survey that included asthma patients aged 18–50 years 
with at least two prescriptions for asthma treatment in 
the past two years. In the Netherlands, 855 respondents 
completed the REALISE survey. Patients with COPD as 
a comorbidity were excluded from the main study analy-
sis. Patients with asthma and concomitant COPD were 
analyzed separately. In accordance with Dutch regulations, 
ethical approval and additional written informed consent 
was not required for this post hoc analysis, as all study 
data were anonymised.
Tools and Indicators
The REALISE questionnaire was developed by the core 
study members (fully listed in the acknowledgements) and 
required approximately 30 minutes for completion. The 
survey made use of validated consumer panels. These 
panels met the International Organization for 
Standardization (ISO:20,252) quality standards. Multiple 
panels were used to reduce potential bias. Detailed infor-
mation on the REALISE study design, population, sample 
size, tools, and processes are reported in the REALISE 
study’s protocol.2
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SABA use was categorized into two groups of patients 
either using more of less SABA than the recommended 
threshold: <3 (low SABA users) or ≥3 (high SABA users) 
times in the last week. Indicators of asthma symptoms 
included the number of days with symptoms, normal 
activities affected by symptoms, and awakening at night, 
all during the 7 days preceding the survey. Indicators of 
exacerbations over the last 12 months included the number 
of antibiotics and oral steroid courses needed due to the 
worsening of asthma symptoms (defined as moderate 
exacerbations), the number of emergency department visits 
and overnight hospital stays due to asthma (defined as 
severe exacerbations).
Statistical Analysis
Statistical analysis was performed using IBM SPSS (ver-
sion 25) and all tests were two-tailed at a 0.05 level of 
significance. Differences in indicators of asthma symp-
toms and exacerbations were assessed using the chi- 
square test or Fisher’s exact test for the dichotomous 
variables and the Mann–Whitney U-test for non-normally 
distributed continuous variables. Descriptive statistics 
were used to describe the respondent’s demographics and 
characteristics.
Binary logistic regression modelling was used to investi-
gate the relation between SABA use (below or above the 
threshold recommended in guidelines) and moderate and 
severe exacerbations. Adjustments were made for the follow-
ing potential confounders: age, gender and ICS-containing 
treatment. Additional confounders (comorbidities, smoking 
status and number of years since asthma diagnosis) were 
added based on their univariate relation (p<0.20) with the 
dependent or independent variable if the maximum number 
of parameters for a model, set at 10% of the lowest number 
of events, was not exceeded. Comorbidities (COPD, dia-
betes, depression, heart disease, high blood pressure, rheu-
matoid arthritis and cancer) were combined into 
a combination score, based on the Charlson Comorbidity 
Index’s scoring system.17 Our combined comorbidity score 
ranges from 0 to 8; one point for each comorbidity with the 
exception of cancer, which counts for two points.
Results
Frequency of SABA Use
Of the 855 Dutch participants who completed the 
REALISE survey, 817 patients with asthma answered the 
question regarding SABA use (“Thinking about the last 
week. How many times have you used your reliever inha-
ler? (This is usually a blue colour)”). Of these 817 respon-
dents, 81 had a co-diagnosis of COPD. The final study 
population, therefore, consists of 736 respondents with 
asthma. Of the 736 respondents, 73.4% (n=540) were 
female, and the median age was 36 years.
Of the 736 respondents, 60.1% (n=442) used SABA ≥3 
times in the last week. An additional 18.6% (n=137) used 
SABA 1 or 2 times and 21.3% (n=157) did not use any 
SABA in the last week (Figure 1).
The largest group of high SABA users (42.8%) was 
41–50 years old, while this was 26–40 years for low 
SABA users (42.5%). Further variations were observed 
in co-morbidities and treatment type. High SABA users 
were significantly more frequently treated with 
a combination inhaler (ICS/LABA) or oral treatment (the 
type of oral treatment was not specified) in comparison to 
low SABA users, respectively, 34.4% vs 25.2%, p=0.009; 
20.1% vs 6.5% p<0.001 (Table 1).
Differences in Patient Outcomes Based 
on SABA Use
A total of 58.4% (n=258) of the high SABA users, and 
42.9% (n=126) of the low SABA users reported using an 
antibiotic course for an asthma-associated condition more 
than once in the last 12 months (p<0.001) (“How many 
times in the past year have you needed a course of anti-
biotics because you experienced other health problems 
related to your asthma, e.g. chest infections/bronchitis/ 
stubborn cough etc?”). (Figure 2)
Similarly, 45.5% (n=201) of the high SABA users and 
21.8% (n=64) of the low SABA users, reported using an 
oral steroid course for worsening of asthma more than 
once in the last 12 months (p<0.001) (“How many times 
have you needed a course of steroid tablets for worsen-
ing asthma? (In the last 12 months …)”). In total 14.9% 
(n=66) of the high SABA users and 3.4% (n=10) of the 
low SABA users had one or more emergency department 
visit due to asthma in the last 12 months (p<0.001) 
(“How many times have you been treated in Accident 
and Emergency or the hospital emergency department for 
your asthma in the past 12 months?”). Finally, 8.4% 
(n=37) of the high SABA users and 1.4% (n=4) of the 
low SABA users had one or more overnight hospital stay 
due to asthma in the last 12 months (p<0.001) (“How 
many times have you been hospitalised and had to stay 
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overnight in a hospital as a result of your asthma in the 
past 12 months?”) (Figure 2).
No significant differences were found between the two 
SABA groups when testing for the indicators of asthma 
symptoms. A slight majority, 55.0% (n=243) of the high 
SABA users and 56.5% (n=166) of the low SABA users 
reported that their normal activities were not affected by 
symptoms (“How many days has asthma interfered with 
your normal activities (eg sport, school, work/housework)? 
(Thinking about the last 7 days …)”) (Figure 3A) and 
48.9% (n=216) of the high SABA users and 50.3% 
(n=148) of the low SABA users did not have any night-
time awakenings due to asthma symptoms (“How many 
nights have you been affected/woken up by asthma symp-
toms (including cough)? (Thinking about the last 7 
days …)”) (Figure 3B). Nevertheless, 81.4% (n=360) of 
the high SABA users and 78.6% (n=231) of the low 
SABA users reported 1 or more days with asthma-related 
symptoms (“How many days have you experienced 
asthma symptoms? (Thinking about the last 7 days …)”) 
(Figure 3C).
A multiple logistic regression analysis revealed that 
high SABA users more frequently experienced moderate 
and severe exacerbations independently of confounders 
(OR 1.8 (95% CI 1.3–2.5) and OR 4.4 (95% CI 2.3–8.7), 
respectively) (Table 2). The logistic regression models of 
the other exacerbation variables are shown in the 
Supplementary Table S1.
Controller Use
A total of 68.3% (n=142) of the high SABA users who 
reported having been prescribed a controller inhaler 
(n=208), indicated in the survey that they use this inhaler 
every day. In contrast, less than half (49.6% (n=59)) of the 
low SABA users on controller therapy (n=119), indicated 
using their controller inhaler every day (“Which statement 
best describes how you take your regular asthma treat-
ment. This is your preventer inhaler, which is usually 
brown, orange or red.”).
Asthma and Concomitant COPD
Similar analyses were also performed for all 817 
patients who completed the question regarding SABA 
use, including on data from the 81 asthma patients with 
co-existing COPD. These results are presented in 
Supplementary Table S2 and Supplementary Figures 
S1–S3. In this subgroup of 81 asthma patients with co- 
existing COPD, 77.8% (n=63) used SABA ≥ 3 times in 
the last week. Furthermore, 14.8% (n=12) reported using 
SABA 1 or 2 times and 7.4% (n=6) did not use any 
Figure 1 SABA usage in the last week (n=736). 
Notes: Survey question: “Thinking about the last week. How many times have you used your reliever inhaler? (This is usually a blue colour)”; The reported percentages are 
rounded to whole numbers.
https://doi.org/10.2147/JAA.S292943                                                                                                                                                                                                                                   
DovePress                                                                                                                                                      
Journal of Asthma and Allergy 2021:14 854
Baron et al                                                                                                                                                            Dovepress
































































SABA in the preceding week (Supplementary Figure 
S4). Of these 81 asthma patients with COPD, the high 
SABA users more frequently visited the emergency 
department and had one or more overnight hospital 
stays in the last 12 months than the low SABA users 
(Supplementary Figure S5). There were no significant 
differences between both SABA groups with regard to 
asthma symptoms (Supplementary Figure S6).
Table 1 Demographics and Characteristics as Reported by Respondents According to SABA Use (n=736)
Respondents with <3 SABA (Low- 
SABA Users) in the Last Week 39.9% 
(n=294)
Respondents with ≥3 SABA (High- 




Female 75.2% (n=221) 72.2% (n=319) P=0.395
Male 24.8% (n=73) 27.8% (n=123)
Age, years, median [IQR] 34 [25–42] 38 [29–45] P<0.001
Age range, years, % (n)
18–25 25.5% (n=75) 17.0% (n=75) P=0.003
26–40 42.5% (n=125) 40.3% (n=178)
41–50 32.0% (n=94) 42.8% (n=189)
Year since asthma diagnosis, % (n)
Data available 83.3% (n=245) 88.5% (n=391)
1 or less 5.7% (n=14) 7.2%(n=28) P=0.478
2–5 12.7% (n=31) 10.5% (n=41)
6–10 15.9% (n=39) 12.8% (n=50)
11 or more 65.7% (n=161) 69.6% (n=272)
Current smokers, % (n) 25.9% (n=76) 24.0% (n=106) P=0.601
Co-morbidities*, % (n)
Diabetes 3.1% (n=9) 7.0% (n=31) P=0.020
Depression 14.6% (n=43) 15.4% (n=68) P=0.834
Heart disease 1.4% (n=4) 2.3% (n=10) P=0.425
High blood pressure 7.5% (n=22) 14.0% (n=62) P=0.006
Rheumatoid arthritis 4.1% (n=12) 8.6% (n=38) P=0.017
Cancer 0.7% (n=2) 1.4% (n=6) P=0.487
Comorbidity Index
0 74.8% (n=220) 63.8% (n=282) P=0.002
1 20.7% (n=61) 24.9% (n=110)
2 2.7% (n=8) 9.3% (n=41)
3 1.0% (n=3) 1.6% (n=7)
4 0.7% (n=2) 0.5% (n=2)
5 0.0% (n=0) 0.0% (n=0)
6 0.0% (n=0) 0.0% (n=0)
7 0.0% (n=0) 0.0% (n=0)
8 0.0% (n=0) 0.0% (n=0)
Treatment type#, % (n)
Reliever (SABA) 75.9% (n=223) 73.5%(n=325) P=0.723
Preventer (ICS) 40.5% (n=119) 47.1% (n=208) P=0.082
Combination inhaler (ICS/LABA) 25.2% (n=74) 34.4%(n=152) P=0.009
Oral treatment 6.5% (n=19) 20.1% (n=89) P<0.001
Other asthma medication 5.4% (n=16) 14.5% (n=64) P<0.001
Notes: *Self-reported as having been diagnosed by a doctor; ap values are two sided for the difference between <3 SABA and ≥3 SABA groups (significant differences are 
marked bold); #Which of the following treatments do you currently take to help manage your asthma? - multiple answers possible. 
Abbreviations: SABA, short-acting beta2 agonist; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long acting beta2 agonist.
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This analysis of the Dutch asthmatic population from the 
REALISE study revealed substantial high SABA use: 60% 
of the asthma patients used SABA above the guideline- 
recommended threshold for ICS addition or other step-up 
treatment (<3 times/week). High SABA users (≥3 times/ 
week) experienced more moderate or severe exacerbations 
even after the statistical model was adjusted for 
Figure 2 Indicators of exacerbations (n=736), according to SABA use (<3 times or ≥3 times/week). 
Notes: <3 SABA (Low-SABA users) n=294; ≥ 3 SABA (High-SABA users) n=442; P values are two sided; The reported percentages are rounded to whole numbers. 
•Significant difference p<0.001.
Figure 3 Indicators of asthma symptoms (n=736), according to SABA use (<3 or ≥3 times/week). 
Notes: <3 SABA (Low-SABA users) n=294; ≥3 SABA (High-SABA users) n=442; P values are two sided, (A) p=0.895, (B) p=0.265, (C) p= 0.109; The reported percentages 
are rounded to whole numbers.
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confounders. Nevertheless, no differences in symptoms 
were observed between low SABA users and high SABA 
users; this might, among other explanations, be due to the 
beneficial effect of SABA on symptom reduction.
High SABA Use
The unexpectedly large proportion of high SABA users 
calls for an explanation. It is known that survey partici-
pants tend to give socially desirable answers,18 which, if 
this was the case, would imply that the actual proportion 
of high SABA users maybe even higher. One of the more 
recent studies investigating SABA use is the Australian 
survey of Azzi et al.6 This paper reported an even higher 
percentage of high SABA users (70.1%) than our study. 
However, the situation in Australia is not quite comparable 
to the Netherlands, as in Australia, SABA are sold over the 
counter, ie without a doctor’s prescription.
Association of High SABA Use with 
Exacerbations
Our findings that high SABA users experienced more 
moderate and severe asthma exacerbations and also more 
often had a history of courses of antibiotics and oral 
steroids, are in line with findings in other studies.6,8,19–24 
This could imply that SABA usage in the preceding week 
can be extrapolated to SABA use in the previous year. 
Hence, this shows that a clinically easy and quick way of 
assessing SABA use, ie by merely asking the patient about 
their SABA use in the preceding week, could be an indi-
cator for the risk of future exacerbations.
Association of High SABA Use with 
Symptoms
In our study, there were no signs of significant variations 
between SABA groups with regard to symptoms. 
Nevertheless, other studies have stressed the association of 
SABA overuse with asthma-related symptoms and quality of 
life.6,25 The different outcomes between studies may be 
explained by the differences in methods and investigated 
symptoms. However, the high SABA users in our study 
may have rated their symptoms as less frequent since they 
use their SABA solely to minimize their symptoms. In line 
with this, it is conceivable that high SABA users would 
experience more symptoms when they use their SABA less 
frequently or not at all. Furthermore, it has been reported 
that patients underreport their symptoms because of a lack of 
accurate perception of their actual asthma control. In such 
cases, patients tolerate their symptoms because they per-
ceive them to be their “standard”.26 The possibility that the 
participants in the current survey also underreported their 
symptoms cannot be ruled out.
It seems remarkable and somewhat contradictory that 
approximately 50% of the patients reported that their normal 
activities are not affected by symptoms, whereas only 20% of 
Table 2 Relation Between Moderate (A)/Severe (B) Exacerbations and SABA Use Adjusted for Confounders (n=736)
Predictors Coefficients (SE) p-value OR 95% CI for OR
Lower Upper
A: Relation between moderate exacerbations and SABA use adjusted for confounders
SABA use (0= low SABA users; 1= high SABA user) 0.600 (0.160) P<0.001 1.822 1.332 2.491
Age −0.002 (0.008) 0.777 0.998 0.981 1.014
Gender (0= male; 1= female) −0.511 (0.184) 0.005 0.600 0.418 0.860
Using ICS containing treatment (0= not using ICS; 1= using ICS) 0.037 (0.176) 0.833 1.038 0.735 1.466
Smoking status (0= no smoker; 1= smoker) 0.234 (0.182) 0.200 1.264 0.884 1.807
Comorbidity Index 0.432 (0.123) P<0.001 1.541 1.211 1.961
B: Relation between severe exacerbations and SABA use adjusted for confounders
SABA use (0= low SABA users; 1= high SABA user) 1.485 (0.342) P<0.001 4.417 2.260 8.663
Gender (0= male; 1= female) −1.291 (0.262) P<0.001 0.275 0.165 0.460
Using ICS containing treatment (0= not using ICS; 1= using ICS) −0.041 (0.280) 0.885 0.960 0.554 1.664
Comorbidity Index 0.582 (0.141) P<0.001 1.789 1.357 2.360
Notes: The confounders comorbidities, smoking status and number of years since asthma diagnosis were added to the models based on their relation (p<0.20) with the 
dependent or independent variable. The variable age was not added to model B since the linearity assumption was not met. 
Abbreviations: SABA, Short-acting Beta-agonist; SE, standard error; OR, Odds ratio; CI, Confidence interval; ICS, Inhaled corticosteroids.
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the patients claimed not to have any symptoms at all. 
Moreover, almost half of the patients in our study reported 
that their daily activities were affected or that they had night-
time awakening due to asthma symptoms, and over 45% of 
the patients in our study reported that they experienced 
asthma symptoms 3 or more days per week. These symptoms 
often lead to a higher burden of disease, negatively impacting 
quality of life, or leading to depression, higher asthma-related 
costs and an increased overall risk of exacerbations.6,8,20
SABA Use in Patients with Asthma and 
COPD
Also, patients with both asthma and COPD used their 
SABA inhaler more frequently than the guideline- 
recommended threshold (<3 times/week). The proportion 
of high SABA users in these patients was even higher than 
in the group of patients with only asthma. However, as- 
needed SABA is part of the standard treatment for patients 
with COPD.27 Patients with both asthma and COPD 
experience more symptoms and exacerbations than 
patients with COPD or asthma.28 Therefore, these patients 
may more frequently need their SABA inhaler for symp-
tom reduction. However, there is a limitation to our find-
ings regarding this subgroup, as the studied population 
sample is quite small. Therefore, further research into 
SABA use in patients with both asthma and COPD is 
required.
ICS Underuse
Adherence to ICS is estimated to range between 25% and 
80%.29–31 It is also known that the adherence to ICS varies 
over time, improving towards and immediately after an 
asthma exacerbation. Poor compliance or absent adherence 
to ICS are strongly associated with more frequent 
exacerbations.28 This is the reason why improvement of 
adherence to ICS is a cornerstone element in the treatment 
strategy of asthma control.
Our study showed that more high SABA users reported 
using their controller inhaler on a daily basis (68%) than 
low SABA users (50%). A possible explanation for this 
finding is that high SABA users in this study potentially 
had more asthma symptoms than low SABA users, there-
fore increasing both ICS and SABA usage in conjunction 
with one another. This makes sense as high SABA use is 
associated with more severe disease, which in its turn 
warrants more reliever use. This certainly does not apply 
to the patients with high SABA use who are not using an 
ICS all together. A change in prescribing behavior, ie no 
longer prescribing SABA on an as needed basis, but initi-
ating treatment by prescribing an ICS/LABA as recom-
mended in the GINA 2019 guidelines, may prove to be of 
vital impact in the reduction of high SABA use among 
asthma patients.1 Starting treatment with an ICS/LABA 
may help patients to improve their ICS adherence, thereby 
simultaneously treating the underlying disease instead of 
using their SABA as a quick solution to reduce their 
symptoms.
Future Challenges
Future research should focus on assessing patients’ habits, 
behaviors and opinions (next to prescribers’) towards the 
(appropriate) use of SABA.32 In addition, it is important to 
focus on approaches for informing and training asthma 
patients with regard to their symptoms and asthma control. 
The type of SABA inhaler also deserves prompt attention 
both in terms of future research goals and GPs’ daily 
prescription practices.21 Overall, questions remaining to 
be addressed are how asthma care could be improved, 
received and adopted and how appropriate use of SABA 
could be comprehended and managed by the GP, but also 
by other healthcare professionals and the patient.16
Strengths and Limitations
The findings of the current study convey new insights on 
high SABA use and differences in symptoms and exacer-
bations in a Dutch asthmatic population. Although the 
nature of the study design, which is an online survey, 
may have inserted some limitations, our findings could 
support future research hypotheses and highlight several 
challenges.
The core limitation is information-bias and recall-bias 
due to the fact that all data were self-reported and could 
not be clinically verified. Therefore, inaccurate responses 
due to poor recall cannot be excluded. Furthermore, the 
fact that this population was not derived from the general 
Dutch population but from consumer panels and included 
only those aged 18–50 years using social media, may 
restrict the generalizability of the findings. However, it is 
believed that it will not have a significant effect on the 
study conclusions since the majority of the wider Dutch 
population is familiar with social media. Nonetheless, it 
cannot be excluded that the people signing up for the 
consumer panels may have different characteristics than 
those who do not sign up, and may therefore, have biased 
our results.
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Unfortunately, asthma severity and medication, specifi-
cally adherence, was only a small aspect of the REALISE 
survey. Therefore, no information regarding the asthma sever-
ity of the patients was available, nor detailed information 
regarding the usage of ICS, including the duration of the 
treatment and adherence. Because of this, no thorough exam-
ination of the asthma severity and ICS adherence for the high 
SABA users and the low SABA users could be performed.
Unfortunately, there was no information available 
regarding patients’ reasons for high use of SABA. 
However, previous research has established several rea-
sons for SABA overuse; 1) patients are not aware that high 
SABA use is an indicator for poor asthma control, 2) 
patients feel an emotional attachment to their SABA relie-
ver, due to its ability to quickly relieve symptoms, and 3) 
patients do not understand the necessity for ICS usage, 
especially when they do not experience symptoms. On 
a side note, it has been observed that severe exacerbations 
temporarily improve adherence to ICS.33
Furthermore, it is important to note that in our study use of 
SABA in de preceding week is associated with exacerbations 
in the last 12 months. Our results could therefore be biased by 
reverse causality. Nevertheless, the relationship between 
SABA use and exacerbation rate was also demonstrated in 
studies measuring SABA overuse based on the number of 
canisters used in the last year.24 This could imply that SABA 
usage in the preceding week can be extrapolated to SABA use 
in the last year. This would make for a clinically easily 
accessible and quick way to assess SABA use, and apply 
this as an indicator for future exacerbation risk.
Taking into consideration the aforementioned limita-
tions, the study still offers valuable insights in the use of 
SABA, specifically for the Dutch asthmatic population. In 
addition, many of these findings seem directly relevant as 
well to other European countries with similar asthma care.
Conclusions
Asthma control in the Netherlands remains poor, in line with 
the pattern observed in other European countries.2 This poor 
control is associated with high use of SABA. Although tools 
and clinical guidelines are widely available, there is still 
a marked gap between guidelines and daily practice. 
Symptoms and exacerbations are common in this Dutch 
asthmatic population, while exacerbations tend to vary sig-
nificantly between low SABA users and high SABA users. 
Such symptoms and exacerbations may result in a strong 
adverse impact on patients’ quality of life, hospitalizations 
and asthma-related deaths. Both healthcare providers and 
patients should interpret high SABA use more diligently as 
a marker of poor asthma control. To change their behaviours, 
more effective interventions are needed to improve asthma 
care and reduce SABA (over)use.
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